Morgan Stanley Maintains Equal-Weight on Simply Good Foods, Lowers Price Target to $39
Morgan Stanley analyst Pam Kaufman maintains Simply Good Foods (NASDAQ:SMPL) with a Equal-Weight and lowers the price target from $41 to $39.
Morgan Stanley Maintains Equal-Weight on Haemonetics, Raises Price Target to $70
Morgan Stanley analyst Drew Ranieri maintains Haemonetics (NYSE:HAE) with a Equal-Weight and raises the price target from $60 to $70.
Truist Securities Maintains Buy on Primerica, Lowers Price Target to $150
Truist Securities analyst Mark Hughes maintains Primerica (NYSE:PRI) with a Buy and lowers the price target from $163 to $150.
Morgan Stanley Maintains Underweight on General Mills, Raises Price Target to $66
Morgan Stanley analyst Pamela Kaufman maintains General Mills (NYSE:GIS) with a Underweight and raises the price target from $56 to $66.
Jim Cramer Says This Stock Is ‘Too Risky’
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Cadre Holdings Inc (NYSE: CDRE) as it "makes things, does stuff, sells at a profit, gives you money back."
Morgan Stanley Maintains Underweight on Consolidated Edison, Raises Price Target to $76
Morgan Stanley analyst David Arcaro maintains Consolidated Edison (NYSE:ED) with a Underweight and raises the price target from $71 to $76.
Why Nio Stock Is Rising Today
NIO Inc (NYSE: NIO) shares are trading higher Friday after the company provided a delivery update for June, as well as the second quarter.
GM Says Sales To Commercial, Government And Rental Fleets Grew 29% YoY; Says Saw ‘Significant pent-up demand for GM vehicles amid low inventories’
https://investor.gm.com/news-releases/news-release-details/gm-continued-gain-us-market-share-and-extended-its-truck
GM Releases PR On Business Update
https://investor.gm.com/news-releases/news-release-details/gm-continued-gain-us-market-share-and-extended-its-truck
AstraZeneca Shares Data At EASL And ESMO World GI For IMFINZI Combinations In Patients With Liver And Biliary Tract Cancers
survival vs. sorafenib in patients with unresectable liver cancer regardless of baseline liver functional reserve
TOPAZ-1 Phase III trial subgroup analysis showed the addition of IMFINZI to standard-of-care chemotherapy